FDA Inspection 1246113 — Narodowe Centrum Badan Jadrowych

Narodowe Centrum Badan Jadrowych — FEI 3008592343

The FDA completed an inspection of Narodowe Centrum Badan Jadrowych on May 24, 2024 in Otwock. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
May 24, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Otwock (Poland)

Additional Details

Mutual Recognition Agreement (MRA)